Helén Tuvesson new CEO of Active Biotech AB from July 1, 2017

19.06.17 15:30
Helén Tuvesson new CEO of <strong>Active Biotech</strong> AB from July 1, 2017


Lund - Active Biotech AB (Nasdaq Stockholm: ACTI) today announces that the Board has appointed the company's current CSO Helén Tuvesson as new CEO of Active Biotech AB. Helén Tuvesson will take up the position on July 1, 2017, replacing Tomas Leanderson, who has been the company's CEO since 2008.

Helén Tuvesson has a broad experience in drug development after more than 20 years in the pharmaceutical industry. Helén has held various senior positions in Active Biotech and since 2011 she has been responsible for the company's research and development.

"I am proud and glad that in Helén Tuvesson we have an internal candidate who can take responsibility as CEO, ensuring continuity and a controlled handover. Helén has been instrumental in the structural changes made in the company during 2016/2017 and has a solid industry experience. I am convinced that she has the qualities required to shape the company's future strategy and maximize its opportunities," says Mats Arnhög, Chairman of the Board.

"I would also like to thank Tomas Leanderson for his significant contribution to the company's business for a long period. Tomas Leanderson will be at the company's disposal during a transitional period," said Mats Arnhög.

"I am very happy and at the same time humbled for the confidence to lead Active Biotech further. I am well acquainted with the company's projects and its potential and look forward to developing the portfolio further and creating value for the company," says Helén Tuvesson.

Lund June 19, 2017

Active Biotech AB (publ)

For further information, please contact:

Mats Arnhög

Chairman of the Board

Tel +46 8 54503770

Mobil: +46 705 915096

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/ inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Anyara, cancer immunotherapy, previously in clinical Phase 1-2/3 development in patients with pancreatic-, lung- or renal cancer. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.

Active Biotech AB

(Corp. Reg. No. 556223-9227)

Box 724, SE-220 07 Lund, Sweden

Tel: +46 (0)46 19 20 00

This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 15.30 a.m. CET on June 19, 2017.

Helén Tuvesson new CEO of Active Biotech AB from July 1, 2017

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Globenewswire


Breaking News

Kurs- und weitere Informationen zum Thema:

Active Biotech

Aktuelle Diskussionen zum Thema:

Active Biotech - Rebound alter ... (09.11.18)

Aktuelle Nachrichten zum Unternehmen:

Active Biotech AB bricht nach en. (01.08.11)
Active Biotech bricht nach enttäus. (01.08.11)
Evotec und Active Biotech vereinb. (06.06.11)
Evotec und Active Biotech unterze. (11.03.10)

Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Active Biotech
Weitere Meldungen
19.06 Helén Tuvesson new CEO o.
19.06 NADL - Announces contract.
19.06 Ad hoc: CropEnergies erhöh.
19.06 Ad hoc: ICHOR Coal N.V.: .
19.06 187,133 Orion Corporation A.
19.06 Ad hoc: Bestandsentwickler .
19.06 Ad hoc: paragon AG beschl.
19.06 Marathon Asset Managemen.
19.06 Ad hoc: Ad-hoc: Preisspann.
19.06 EQS-Adhoc: Conzzeta: Stark.
18.06 EQS-Adhoc: AEVIS VICTOR.
17.06 Ad hoc: Pyrolyx AG: Fremd.
17.06 DBV Technologies Highlights.
16.06 Schrader Cellars Entrusts Co.
16.06 Fortis settlement not declare.
16.06 Ad hoc: Constantin Medien .
16.06 ArcelorMittal led consortium .
16.06 Songa Offshore SE : Manda.
16.06 Nordic Mines AB (publ) and.
16.06 Ad hoc: ADLER Real Estat.
16.06 FDA posts briefing materials.
16.06 Bavarian Nordic Announces .
16.06 Annual General Meeting of .
16.06 Voting Results from Conste.
16.06 Volta Finance Limited : Net .
16.06 Exercise of call options
16.06 Bavarian Nordic Provides Up.
16.06 Odfjell SE signs Term Shee.
15.06 DBV Technologies Announce.
15.06 DBV Technologies Announce.

Welche Social Networks nutzen Sie meistens?
Linked in

Stimmen: 42232 , Ergebnis

Status: nicht eingeloggt

Registrieren | Passwort vergessen?
Im Bereich Nachrichten:
Barrick Gold: Vorsicht - Trendbruch!
Experte: Stefan Hofmann, STOCK-WORLD
DAX scheitert erneut mit ...
CMC Markets, (18:50)
Experte: CMC Markets,
DAX gibt nicht auf!
Christian Zoller, www.boerse-daily.de (16:55)
Experte: Christian Zoller, www.boerse-daily.de
Centurion erhält ...
Björn Junker, GOLDINVEST.de (16:01)
Experte: Björn Junker, GOLDINVEST.de
Sorgenkind Europa
Michael Beck, Leiter Po., Bankhaus ELLWANGER. (15:46)
Experte: Michael Beck, Leiter Portfolio M., Bankhaus ELLWANGER & GEIGER K.
Bayer: Bei den ...
Volker Gelfarth, (15:31)
Experte: Volker Gelfarth,
Rohöl: Ölförderer reagieren ...
Heiko Geiger, Bank Vontobel Europe . (15:00)
Experte: Heiko Geiger, Bank Vontobel Europe AG
DAX: Das könnte spannend ...
Cornelia Frey, Börse Stuttgart AG (15:00)
Experte: Cornelia Frey, Börse Stuttgart AG
BYD: Die Bullen setzen ...
Robert Sasse, (14:41)
Experte: Robert Sasse,
First Berlin - M1 Kliniken ...
First Berlin Equity Rese., (14:23)
Experte: First Berlin Equity Research,
MorphoSys will sämtliche ...
Christian-Hendrik Knappe, Produktexperte X-marke. (14:13)
Experte: Christian-Hendrik Knappe, Produktexperte X-markets, Deutsche Ba.
Kupfer: Steht ein ...
Jürgen Sterzbach, boerse-daily.de (13:25)
Experte: Jürgen Sterzbach, boerse-daily.de
Luftig, sportlich, teuer? ...
wikifolio.com, (12:55)
Experte: wikifolio.com,
Niquet's World
Neues vom Portal
Bitcoin: Ausgesprochen ruhiges Halbjahr
Letzte Börsen-Meldung
Letzte Börsen-Analyse
Top-Klicks News
Top-Klicks Analysen